School of Medicine
Showing 41-60 of 639 Results
-
Catherine Benedict
Clinical Associate Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry
Current Research and Scholarly InterestsMy research focuses on improving cancer survivorship through better understanding of long-term health outcomes and through the development of theoretically driven, evidence-based behavioral interventions to improve adjustment, risk management, and quality of life. To this end, I lead studies aimed to guide and support patient decision-making and self-management after cancer. Much of my work focuses on the experiences of young adults affected by cancer.
-
Jonathan S. Berek, MD, MMSc
Laurie Kraus Lacob Professor
BioLaurie Kraus Lacob Professor
Stanford University School of Medicine
Director, Stanford Women’s Cancer Center
Senior Advisor, Stanford Cancer Institute
Executive Director, Stanford Health Communication Initiative
Director, MedArts Films
Stanford Center for Health Education
Stanford University -
Dominique Bergmann
Shirley R. and Leonard W. Ely, Jr. Professor of the School of Humanities and Sciences
Current Research and Scholarly InterestsWe use genetic, genomic and cell biological approaches to study cell fate acquisition, focusing on cases where cell fate is correlated with asymmetric cell division.
-
Daniel Bernstein
Alfred Woodley Salter and Mabel G. Salter Endowed Professor of Pediatrics
Current Research and Scholarly Interests1. Using iPSC-derived cardiomyocytes to understand hypertrophic cardiomyopathy and heart failure associated with congenital heart disease.
2. Role of alterations in mitochondrial dycamics and function in normal physiology and disease.
3. Differences between R and L ventricular responses to stress,
4. Immune biomarkers of risk after pediatric VAD implantation.
5. Biomarkers for post-transplant lymphoproliferative disorder. -
Alice Bertaina MD, PhD
Lorry I. Lokey Professor
On Leave from 03/01/2024 To 04/30/2024Current Research and Scholarly InterestsDr. Bertaina is a highly experienced clinician and will play a key role in supporting Section Chief Dr. Rajni Agarwal and Clinical Staff in the Stem Cell Transplant Unit at Lucile Packard Children’s Hospital. She will also continue her research on immune recovery and miRNA, understanding the mechanisms underlying immune reconstitution, Graft-versus-Host Disease (GvHD), and leukemia relapse after allogeneic HSCT in pediatric patients affected by hematological malignant and non-malignant disorders.
-
Carolyn Bertozzi
Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology
BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.
Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). She is now the Baker Family Director of Stanford ChEM-H.
Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, the ACS Award in Pure Chemistry, and the Chemistry of the Future Solvay Prize, among others.
The Bertozzi Group develops chemical tools to study the glycobiology underlying diseases such as cancer, inflammation, tuberculosis and most recently COVID-19. She is the inventor of "bioorthogonal chemistry", a class of chemical reactions compatible with living systems that enable molecular imaging and drug targeting. Her group also developed new therapeutic modalities for targeted degradation of extracellular biomolecules, such as antibody-enzyme conjugates and Lysosome Targeting Chimeras (LYTACs). As well, her group studies NGly1 deficiency, a rare genetic disease characterized by loss of the human N-glycanase.
Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi cofounded Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science LLC and Lycia Therapeutics. She is also a member of the Board of Directors of Lilly. -
Allison Betof Warner, MD, PhD
Assistant Professor of Medicine (Oncology)
BioDr. Betof Warner is a board-certified, fellowship-trained medical oncologist with the Cutaneous Oncology Program and an Assistant Professor in the Department of Medicine, Division of Medical Oncology. She also serves as Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, and co-Director of the Pigmented Lesion and Melanoma Program.
Clinical interests of Dr. Betof Warner include treatment of advanced melanoma, immunotherapy, and cellular therapies for solid tumors. She has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy, which is expected to become standard of care for immunotherapy-refractory melanoma.
Dr. Betof Warner serves as the leader of the Melanoma & Cutaneous Oncology Clinical Research Group, with research interests focused on tumor response to immunotherapy. She has been the principal investigator of multiple clinical trials focusing on immunotherapy-refractory melanoma and is internationally recognized for her expertise in central nervous system metastases and the use of novel cellular therapies. Dr. Betof Warner collaborates with investigators around the world in surgery, neuro-oncology, neurosurgery, radiation oncology, and pathology. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), and Melanoma Research Foundation.
In addition to publishing her research in peer-reviewed journals, Dr. Betof Warner has served as an editorial and grant reviewer for multiple organizations, including the Melanoma Research Foundation. She has authored book chapters and case reports, contributed to national guidelines, and presented her findings at regional, national, and international meetings.
Dr. Betof Warner is a member of multiple professional organizations and societies, including the American Association for Cancer Research, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer, where she serves on the Early Career Scientist Committee. She is also a member of the American College of Sports Medicine and the European Society for Medical Oncology. -
Ami Bhatt
Associate Professor of Medicine (Hematology) and of Genetics
Current Research and Scholarly InterestsThe Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.
-
Michael S Binkley, MD, MS
Assistant Professor of Radiation Oncology (Radiation Therapy)
BioDr. Binkley is a radiation oncologist specializing in lymphoma treatment and an assistant professor in the Stanford University School of Medicine Department of Radiation Oncology.
His clinical expertise includes stereotactic ablative radiotherapy (SABR), total lymphoid and total body irradiation, and intensity modulated radiation therapy (IMRT).
For each patient, Dr. Binkley develops a personalized, comprehensive, and compassionate care plan. His goals are to improve both health and quality of life.
Dr. Binkley has conducted extensive research to advance cancer treatment. In his post-doctoral fellowship at Stanford, he studied the use of genomic signatures to predict response to radiotherapy. His current clinical and laboratory research seek to identify prognostic and predictive clinical, radiographic, and genomic factors to inform individualized treatment strategies.
He has co-authored articles on his research discoveries published in Cancer Discovery, Blood, the International Journal of Radiation Oncology*Biology*Physics, and elsewhere. Topics have included innovations in the treatment of lymphoma and lung cancer.
He also has made invited presentations to colleagues at national and international conferences. He has presented the latest findings on radiation therapy for lung cancer and lymphoma at meetings of the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and International Conference on Malignant Lymphoma (ICML).
Honors for Dr. Binkley include the Malcolm A. Bagshaw Award for leadership and outstanding scientific achievement. This award is named for a pioneer in radiation therapy and former chair of the Departments of Radiology and Radiation Oncology at Stanford University School of Medicine.
Dr. Binkley is a member of the American Society of Clinical Oncology, American Society for Radiation Oncology, and American Association for Cancer Research. He is a founding member of the Global nLPHL One Working (GLOW) Working Group, an international collaboration studying nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in children and adults. -
Francis Blankenberg
Associate Professor of Radiology (Pediatric Radiology) and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsStudies on apoptotic cell death in vivo using the H MRS phenomenon.
-
Helen M. Blau
Donald E. and Delia B. Baxter Foundation Professor, Director, Baxter Laboratory for Stem Cell Biology and Professor, by courtesy, of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsProf. Helen Blau's research area is regenerative medicine with a focus on stem cells. Her research on nuclear reprogramming and demonstrating the plasticity of cell fate using cell fusion is well known and her laboratory has also pioneered the design of biomaterials to mimic the in vivo microenvironment and direct stem cell fate. Current findings are leading to more efficient iPS generation, cell based therapies by dedifferentiation a la newts, and discovery of novel molecules and therapies.
-
Douglas W. Blayney
Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsImproving the quality of cancer care at Stanford, in our network of care, and nationally
-
Nikolas Blevins, MD
Larry and Sharon Malcolmson Professor in the School of Medicine, Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsInner ear microendoscopy -- Developing techniques for minimally-invasive imaging of inner ear microanatomy and neural pysiology. Applications include improved cochlear implant development, inner ear regenerative techniques, inner ear surgery, and auditory physiology.
Microsurgical robotics -- Developing scalable microsurgical instrumentation and robotic techniques for use in head and neck surgery.
Surgical Simulation -- Immersive environment for temporal bone surgical simulation. -
Daniel Bloch
Professor (Research) of Biomedical Data Science (BDS), Emeritus
BioI received my PhD. in Mathematical Statistics in 1967. I joined the research community at the Stanford University School of Medicine, Division of Immunology & Rheumatology, in 1984 as head statistician directing the biostatistics consulting and analytic support of the Arthritis Rheumatism Aging Medical Information System (ARAMIS) and Multipurpose Arthritis Center (MAC) grant-related research programs. In 1993 I was appointed Associate Professor with a joint appointment in the Departments of Medicine and of Health Research & Policy, and am currently Professor of Biostatistics at Stanford University, emeritus since 2007. My contributions to the statistics literature span numerous fields, including methods of sample size estimation, efficiency and bias of estimators, research methods for kappa statistics, non-parametric classification methods and methods of assessing multi-parameter endpoints. I have over 200 peer-reviewed publications. I have been directly involved with the development of numerous criteria rules for classification of diseases and with establishing guidelines for clinical trial research and in proposing responder criteria for osteoarthritis drugs. Since 1987, I have been a consultant on an ad hoc basis to pharmaceutical and biotechnical firms, including both start-up and established companies. I have extensive experience with devices, drugs and biologics and have participated in all aspects of applying statistics to implement investigational plans; e.g.: for protocol development, design of trials, database design. I’ve been a member of the FDA Statistical Advisors Panel, the statistical member on numerous data safety monitoring boards, and frequently represent companies at meetings with the FDA
-
Paul D. Blumenthal, MD, MPH
Professor of Obstetrics and Gynecology (Gynecology-Family Planning) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsImproving Access to Family Planning Services in Low Resource Settings:
Through a collaboration with Population Services International, the Stanford Program for International Reproductive Education and Services (SPIRES) provides technical direction in a program designed to improve access to and uptake of family planning, particularly Long Acting Reversible Contraception (LARC) such as IUDs and implants, in 14 developing countries globally. The first year saw insertion of over 280,000 IUDs. -
Matthew Bogyo
Professor of Pathology and of Microbiology and Immunology and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsOur lab uses chemical, biochemical, and cell biological methods to study protease function in human disease. Projects include:
1) Design and synthesis of novel chemical probes for serine and cysteine hydrolases.
2) Understanding the role of hydrolases in bacterial pathogenesis and the human parasites, Plasmodium falciparum and Toxoplasma gondii.
3) Defining the specific functional roles of proteases during the process of tumorogenesis.
4) In vivo imaging of protease activity -
Sam Bollinger
Ph.D. Student in Cancer Biology, admitted Autumn 2021
BioOriginally from State College, Pennsylvania, Sam graduated with honors from Penn State University with a B.S. in Chemistry and a minor in Biology. He subsequently spent three years working at the Lankenau Institute for Medical Research for Dr. Ellen Heber-Katz. Sam hopes to expand the paradigm of cancer research and help to develop novel therapies for cancer and other ailments. He is also interested in optimization of physical and mental performance.
-
Melissa L Bondy
Stanford Medicine Discovery Professor, Professor of Epidemiology and Population Health and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsPrincipal Investigator, Discovery, Biology and Risk of Inherited Variants in Glioma, 1R01CA217105-01A1, NIH/NCI, 05/01/2018-06/30/2022, MPI (Contact PI)
Principal Investigator, Characterizing Germline and Somatic Alterations by Glioma Subtypes and Clinical Outcome, 1R01CA232754-01, 07/01/2019-06/30/2023, MPI (Contact PI)
Co-Leader (Project), SPORE in Brain Cancer, PI – Fred Lang (Sub with MD Anderson), 2 P50CA127001-11, 09/01/2019-08/31/2023
Co-Investigator, Stanford University Cancer Center, PI – Steve Artandi, P30 CA124435, NCI, 09/15/10-05/31/22
Co-Investigator, Ovarian Cancer Survival in African-American Women, PI, Joellen Schildkraut, R01 CA237318-01A1, NIH/NCI, 07/01/2020-06/31/2025 -
Donna M. Bouley, DVM, PhD
Professor of Comparative Medicine at the Stanford University Medical Center, Emerita
Current Research and Scholarly InterestsResearch interests: ocular pathology, host-pathogen interactions in infectious disease, infectious disease in frogs, phenotypic characterization of tg and ko mice, histopathology of minimally-invasive radiological ablation techniques (focused ultrasound, cryoablation).
